上海医药2025年上半年净利润同比增长51.56%

Core Viewpoint - Shanghai Pharmaceuticals announced a revenue of 141.593 billion yuan for the first half of 2025, representing a year-on-year growth of 1.56% [2] - The net profit attributable to shareholders reached 4.459 billion yuan, showing a significant year-on-year increase of 51.56% [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 2.1 billion yuan, reflecting a year-on-year decline of 22.38% [2] Financial Performance - Revenue for the first half of 2025: 141.593 billion yuan, up 1.56% year-on-year [2] - Net profit attributable to shareholders: 4.459 billion yuan, up 51.56% year-on-year [2] - Net profit after deducting non-recurring items: 2.1 billion yuan, down 22.38% year-on-year [2]